Abstract
The Director's Forum series is written and edited by Robert Weber and Scott Mark and is designed to guide pharmacy leaders in establishing patient-centered services in hospitals and health systems. As the Food and Drug Administration (FDA) approval process becomes more stringent with regard to postmarketing surveillance for medications, directors of pharmacy will need to understand expectations of inpatient pharmacy services to ensure patient safety and meet requirements. This article provides background information regarding the FDA Risk Evaluation and Mitigation Strategies (REMS) programs and potential implications for hospital pharmacy.
Get full access to this article
View all access options for this article.
References
1.US Food and Drug Administration. Regulatory information: legislation: Federal Food, Drug, and Cosmetic Act (FD…C Act): Food and Drug Administration Amendments Act (FDAAA) of 2007. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FoodandDrugAdministrationAmendmentsActof2007/default.htm. Accessed April 22, 2010.
2.US Food and Drug Administration. FDA Issues draft guidance on risk evaluation and mitigation strategies. September 30, 2009. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm184399.htm. Accessed April 22, 2010.
3.US Food and Drug Administration. What we do: history. http://www.fda.gov/AboutFDA/WhatWeDo/History/default.htm. Accessed April 13, 2010.
4.US Food and Drug Administration. About FDA: FDA basics. http://www.fda.gov/AboutFDA/Basics/ucm194877.htm. Accessed April 13, 2010.
5.US Food and Drug Administration. News & events: newsroom: press announcements. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm204236.htm. Accessed April 14, 2010.
6.US Food and Drug Administration: About FDA: FDA basics. http://www.fda.gov/AboutFDA/Basics/ucm194909.htm. Accessed April 13, 2010.
7.The Federal Register. Administrative Procedure Act: United States Code , Title 5, Part 1, Chapter 5 Subchapter II. http://www.archives.gov/federal-register/laws/administrativeprocedure/552a.html. Accessed April 14, 2010.
8.Govtrack. Congress: legislation: HR 3580: Food and Drug Administration Amendments Act of 2007. http://www.govtrack.us/congress/bill.xpd?bill=h110-3580. Accessed April 13, 2010.
9.
Traynor K.
Risk-Management plan for opioid drugs proves slow going . Am J Health Syst Pharm. 2009 ; 66 (14 ): 1242 –1243 .
10.US Food and Drug Administration. Drugs: drug safety and availability: postmarket drug safety information for patients and providers. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm. Accessed April 13, 2010.
11.Amgen. Aranesp REMS. http://wwwext.amgen.com/pdfs/products/ESA_REMS_Aranesp.pdf. Accessed April 15, 2010.
12.
BL103951 Aranesp (darbepoetin alfa). http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM200104.pdf. Accessed April 18, 2010.
13.About Nplate™ NEXUS. http://www.nplatenexus.com/about.html. Accessed April 19, 2010.
14.ASHP Advantage. E-Newsletter. FDAAA. Winter 2010 . http://www.ashpadvantage.com/fdaaa/fdaaa-winter-newsletter.pdf. Accessed April 19, 2010.
15.US Food and Drug Administration. Drugs: drug safety and availability: information by drug class. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm163647.htm. Accessed April 15, 2010.
16.US Food and Drug Administration. Drugs: drug safety and availability: postmarket drug safety information for patients and providers: FDA Drug Safety Communication: new boxed warning on sever liver injury with propylthiouracil. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm209023.htm. Accessed April 22, 2010.